What’s Next for Pharmaceutical Distribution?

Archbow Consulting Vice President Shannon Hybner and Senior Director Amanda Quintanilla attended this year’s Healthcare Distribution Alliance Distribution Management Conference in Austin, TX, where they engaged with industry leaders on key distribution challenges and innovations. The conference highlighted great content, speakers, and thought leaders,  all collectively asking, “Where do we go from here?”

The Status Quo Won’t Cut It

Keynote speaker Diana Kander emphasized a critical principle she follows: “Being the same as last year is my nemesis.” This sentiment aligns well with the broader industry imperative for continuous evolution and adaptation. In a landscape defined by constant evolution, pharmaceutical manufacturers and their channel partners can no longer rely on yesterday’s playbook to achieve tomorrow’s goals. Those who adapt will thrive; those who don’t risk obsolescence.

We’ve distilled the following takeaways from the conference and developed strategic recommendations to help organizations execute on their 2026 evolution roadmap.

Specialty is Here to Stay…and Getting More Complex

Specialty therapies continue to account for the majority of clinical trials and approved drug launches from 2025 onward, with oncology leading the charge, as expected. Yet growth in this space requires far more than the increased capacity the market has seen in cold chain logistics. Successful specialty launches now demand:

• Extended pre-launch planning (12-18 months minimum) to allow adequate lead time for partner readiness
• Cross-functional collaboration across more disciplines, such as medical, regulatory, and commercial teams, plus external consultants, is needed from day one
• More strategic, narrower network selections that prioritize quality partnerships over network size, requiring more rigorous access validation and proactive customer engagement
• Scalability built into customization to balance product-specific requirements with an eye on long-term operational efficiency

The Challenge: The specialty landscape continues to fragment with new market entrants and M&A activity, making successful navigation increasingly complex without expert guidance.

Archbow’s Solution: We demystify the complexity of specialty programs and products, leveraging years of specialty expertise. Our consulting team will craft customized channel strategies and partner-engagement roadmaps that accelerate time-to-market while minimizing operational risk.

New NDC and Barcode Ruling: A 7-Year Implementation Window Begins Now

On March 6, 2026, the FDA approved a 7-year rollout of the new 12-digit, uniform-format NDC implementation, a decision based on positive feedback from the decade-long DSCSA integration lead time. History tells us what comes next – early adopters who invest in pre-planning, testing, and internal alignment will see smoother execution. At the same time, last-minute implementers will face operational bottlenecks and potentially costly delays.

The Risk: Organizations must prioritize and execute operational NDC changes with urgency to maximize patient access to life-changing therapies.

Archbow’s Solution: We can help manufacturers and channel vendors build a comprehensive action plan that accounts for partner engagement timelines, testing requirements, internal resource constraints, and alignment with the broader strategic priorities, ensuring the organization is ahead of the NDC rollout curve.

DSCSA Challenges Aren’t Disappearing

Despite 10+ years to prepare for its implementation, DSCSA remains a pain point across the industry. Persistent issues affecting all supply chain entities include data integrity gaps, siloed sectoral communication, exceptions management breakdowns, and quarantined inventory tied up awaiting accurate serialization data. Operational barriers can potentially impact revenue while compromising patient access to life-changing therapies.

The Problem: Reactive serialization management can lead to missed sales opportunities, operational headaches, and weakened customer relationships.

Archbow’s Solution: We can assess an organization’s current trade structure, clarify role definitions, and identify opportunities or gaps in exceptions management processes. Optimized standard operating procedures that accelerate product distribution, ensure regulatory compliance, and strengthen customer relationships are the goal.”

• Additional Considerations for Pharmaceutical Leaders Upcoming State Licensing Reforms: New rulings in 2026 for wholesale/distributor and 3PL licenses could reshape and help simplify regulatory requirements across states. Archbow will monitor state regulatory responses to this ruling and their immediate channel implications.
• The Affordability Pressure Is Real: The Federal Government’s focus on affordability isn’t dissipating anytime soon. Pharmaceutical pricing rules, 340B reimbursement pressures, and political uncertainty could directly impact manufacturer margins and channel growth going forward. Organizations must implement proactive strategic planning now to mitigate exposure to market volatility. Temperature Management Misalignment: United States Pharmacopeia’s (USP’s) global supply chain guidance and standards don’t always align with U.S. manufacturers’ product-specific requirements, creating confusion across partners. Establishing clear temperature management documentation, aligning processes, and executing comprehensive partner education help organizations achieve launch success from day one.”
• Embrace AI-Driven Innovation: The most transformative channel and operational improvements are still ahead. Organizations that adopt AI tools to enhance team efficiency today will outpace competitors tomorrow.

Ready to Navigate the Distribution Landscape?

The pharmaceutical distribution industry is at an inflection point, now more than ever. Specialty growth, regulatory complexity, margin pressures, and technology advancements demand more than incremental adjustments. At Archbow, we partner with forward-thinking manufacturers to build resilient, scalable channel strategies that drive successful results in this evolving market.

Organizations navigating 2026 evolution priorities require strategic support. Archbow Consulting delivers real-world expertise across specialty therapy launches, new regulatory requirements, and distribution network optimizations. Contact our distribution team today to learn more.